| 2023/06/19 | 新源生技 Allgenesis says dry eye patients’ trial data ‘encouraging’ |
| 2023/06/19 | <乾眼症> 新源生技 Allgenesis： 臨床1數據顯示 AG-80308能治療多種乾眼症的徵兆和症狀 |
| 2023/05/25 | 蔼睦醫療合作夥伴 新源生技 Allgenesis發佈AG-73305治療糖尿病性黃斑水腫2a期臨床初步安全性和有效性數據 |
| 2023/05/25 | 新源生技 Allgenesis announces preliminary safety and efficacy data from AG-73305 Phase 2a trial for treatment of DME |
| 2023/05/24 | 新源生技 Allgenesis touts preliminary data from Phase IIa diabetic macular edema trial |
| 2023/05/23 | 新源生技 Allgenesis：Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema |
| 2022/10/18 | 新源生技 Allgenesis: Taiwan-developed novel ophthalmic drug enters 2nd clinical trial in U.S. |
| 2022/10/18 | 新源生技 Allgenesis：從實驗室到臨床—糖尿病黃斑水腫新藥成果發表 國科會基礎研究與產學合作成果進入第二期臨床試驗 |
| 2023/06/20 | 新源生技 Allgenesis：first-in-class乾眼新藥1b臨床主觀客觀症狀均改善 |
| 2021/09/03 | 新源生技 Allgenesis：黃斑部病變眼科新藥AG-73305授權眼科新創AffaMed |
